> Details

Harbeck, Nadia [Author]; von Schumann, Raquel [Author]; Kates, Ronald Ernest [Author]; Braun, Michael [Author]; Kuemmel, Sherko [Author]; Schumacher, Claudia [Author]; Potenberg, Jochem [Author]; Malter, Wolfram [Author]; Augustin, Doris [Author]; Aktas, Bahriye [Author]; Forstbauer, Helmut [Author]; Tio, Joke [Author]; Grischke, Eva-Maria [Author]; Biehl, Claudia [Author]; Liedtke, Cornelia [Author]; De Haas, Sanne Lysbet [Author]; Deurloo, Regula [Author]; Wuerstlein, Rachel [Author]; Kreipe, Hans Heinrich [Author]; Gluz, Oleg [Author]

Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer
  • Contributor: Harbeck, Nadia [Author]; von Schumann, Raquel [Author]; Kates, Ronald Ernest [Author]; Braun, Michael [Author]; Kuemmel, Sherko [Author]; Schumacher, Claudia [Author]; Potenberg, Jochem [Author]; Malter, Wolfram [Author]; Augustin, Doris [Author]; Aktas, Bahriye [Author]; Forstbauer, Helmut [Author]; Tio, Joke [Author]; Grischke, Eva-Maria [Author]; Biehl, Claudia [Author]; Liedtke, Cornelia [Author]; De Haas, Sanne Lysbet [Author]; Deurloo, Regula [Author]; Wuerstlein, Rachel [Author]; Kreipe, Hans Heinrich [Author]; Gluz, Oleg [Author]
  • Published: Basel: MDPI, [2023]
  • Published in: Cancers ; 13,19, (2021)
  • Language: English
  • Keywords: hormone receptor-positive ; biomarkers ; breast cancer ; immune markers ; HER2-positive
  • Origination:
  • Footnote:
  • Description: Prognostic or predictive biomarkers in HER2-positive early breast cancer (EBC) may inform treatment optimization. The ADAPT HER2-positive/hormone receptor-positive phase II trial (NCT01779206) demonstrated pathological complete response (pCR) rates of ~40% following de-escalated treatment with 12 weeks neoadjuvant ado-trastuzumab emtansine (T-DM1) ± endocrine therapy. In this exploratory analysis, we evaluated potential early predictors of response to neoadjuvant therapy. The effects of PIK3CA mutations and immune (CD8 and PD-L1) and apoptotic markers (BCL2 and MCL1) on pCR rates were assessed, along with intrinsic BC subtypes. Immune response and pCR were lower in PIK3CA-mutated tumors compared with wildtype. Increased BCL2 at baseline in all patients and at Cycle 2 in the T-DM1 arms was associated with lower pCR. In the T-DM1 arms only, the HER2-enriched subtype was associated with increased pCR rate (54% vs. 28%). These findings support further prospective pCR-driven de-escalation studies in patients with HER2-positive EBC.
  • Access State: Open Access
  • Rights information: Attribution (CC BY)